TITLE

IMMUNE NETWORK HALTS PHASE I INTERACTION TRIAL

PUB. DATE
May 2001
SOURCE
Worldwide Biotech;May2001, Vol. 13 Issue 5, p1
SOURCE TYPE
Trade Publication
DOC. TYPE
Article
ABSTRACT
Announces the interruption of the Canadian Phase I drug interaction clinical study of Immune Network Ltd.
ACCESSION #
4425594

 

Related Articles

  • Herbal TB Immunotherapy Presented in Hong Kong.  // Worldwide Biotech;Aug2011, Vol. 23 Issue 8, p7 

    The article discusses Immune Network Ltd.'s discovery that a tablet version of its Imunoxel (Dzherelo) produced superior results in treating tuberculosis (TB) than its liquid form. These findings were presented by Ekomed at the 3rd Asia Pacific Region Conference of the International Union...

  • IMMUNE NETWORK REPORTS 9-MONTH NET LOSS OF NEARLY $9 MILLION.  // Biotech Financial Reports;Jan2002, p1 

    Reports developments involving Immune Network Ltd in Vancouver, British Columbia as of January 2002. Appointment of Mark Glusing as member of the Board of Directors of the company; Highlights of the third-quarter financial results; Commemoration of its Alzheimer clinical trial project.

  • Pipeline preview.  // Formulary;Feb2003, Vol. 38 Issue 2, p78 

    Reports on drug developments in the U.S. as of February 2003. Telithromycin; Influenza virus vaccine; Carvedibol; Losartan potassium; ABI-007.

  • Risk and benefit evaluation in development of pharmaceutical products Wang, Y.; Aaron, C. S.; Harbach, P. R.; Zimmer, D. M.; Mayo, J. K.; Yu, R. L.; Mattano, S. S. // Environmental Health Perspectives Supplements;1993 Supplement 3, Vol. 101, p291 

    No abstract available.

  • Quicker drug approvals on the way for Europe. Davidson, Sylvia // Nature Biotechnology;Sep2001, Vol. 19 Issue 9, p798 

    Examines proposals to expedite drug approvals in order to increase the competitiveness of the drug development industry in Europe. Significance for the biopharmaceutical industry; Possible increase in the workload of the European Medicines Evaluation Agency; Gap between the U.S. and European...

  • Drug pipelines far from full, report finds. Pines, Noah // McKnight's Long-Term Care News;Oct2012, Vol. 33 Issue 10, p33 

    The article focuses on the company Bernstein Research's report which shows that the success rate of the pharmaceutical pipelines in the U.S. at all stages of drug development is declining or remains flat.

  • Virtual Drug Development Becomes Reality. Sinovic, Steve // San Diego Business Journal;1/10/2011, Vol. 32 Issue 2, p3 

    The article reports on the improvement of the contract research organization (CRO) industry, by establishing drug development initiatives in San Diego, California.

  • Innovation Featured at Drug Discovery Technology 2003. Holland-Moritz, Pamela // Drug Discovery & Development;Sep2003, Vol. 6 Issue 9, p83 

    Highlights products and technology in the drug discovery industry in the U.S., featured at IBC's 8th annual World Congress Drug Discovery Technology 2003. ABgene's Seal-It; Accelrys Inc.'s Discovery Studio platform; Aclara Biosciences Inc.'s eTag Assay System; Ambion Inc.'s Silences validated...

  • EDITOR'S CHOICE.  // Drug Discovery & Development;Sep2003, Vol. 6 Issue 9, p90 

    Features products and technology in the drug development industry in the U.S. Nalge Nunc International's 384 DeepWell Plate and Well Cap Mat; Millipore Corp.'s Ultrafree-DA centrifugal device; Chemicon International Inc.'s SARS OligoDetect assay; QIAGEN GmbH's BioRobot LiquiChip System; Kendro...

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics